公司资料
Liquidia Corporation 股价、新闻与催化剂
- 股票代码:
- LQDA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
77.70 USD (+4.38%)
收盘价
最后更新: 2026年8月17日
4.9B USD
市值
股价为何变动
As of Aug 17, 2026, LQDA closed up 4.38% at $77.70. No new same-company headline was identified in the current news window.
公司概览
Pulmonary Hypertension Company
Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines.
YUTREPIA
YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved in the United States for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
PRINT Technology
Liquidia's PRINT manufacturing platform produces particles with controlled size, shape, and composition. The company uses this capability to create inhaled formulations intended to simplify administration and support dose flexibility.
L606
L606 is a sustained-release inhaled formulation of treprostinil delivered twice daily with a next-generation nebulizer. The pivotal Re-Spire study is evaluating the program in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Clinical Expansion Strategy
Liquidia is conducting multiple studies across YUTREPIA and L606 to generate evidence in established indications and explore additional uses for inhaled treprostinil.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。